Whalesbook
Vaxfab Enterprises Ltd has bolstered its capital base through the successful conversion of warrants. The company announced on April 7, 2026, the allotment of 12,62,229 equity shares, a move that increases its paid-up equity share capital.
The Board of Directors approved the issuance of these shares at ₹21.02 each, with a face value of ₹10 per share. This allotment brings Vaxfab's total paid-up equity share capital to ₹20,87,11,670, equivalent to ₹208.71 crore. The newly issued equity shares rank pari-passu, meaning they carry the same rights as existing shares. This capital infusion directly strengthens the company's equity base.
The funds raised can support operational expansion, debt reduction, or general corporate purposes, thereby enhancing Vaxfab Enterprises' financial structure. For existing shareholders, an increase in the total number of outstanding shares signifies a dilution in their proportionate ownership.
Vaxfab Enterprises has consistently utilized warrant conversions and other mechanisms to raise capital. On March 17, 2026, the company allotted 2,733,903 shares via warrant conversion. Prior to that, on February 13, 2026, it issued 2,686,268 shares at the same price. These follow a September 2025 proposal for a preferential issue of warrants, intended to raise approximately ₹53.59 crore.
While warrant conversions provide necessary capital, persistent dilution can be a concern for existing shareholders. The company has also faced penalties from the BSE for non-filing of shareholding patterns, indicating potential governance lapses that investors should monitor.
Vaxfab Enterprises operates in a sector with peers including Pulsar International, Gujarat Inject (Kerala), MRC Agrotech, and AuSom Enterprise. As of April 2, 2026, Vaxfab's market capitalization was around ₹83.07 crore. The company's stock has seen significant gains over the past year, outperforming the broader market, though it has also experienced rating downgrades and periods of selling pressure. Recent financial results show a consolidated net loss of ₹3.24 crore for the third quarter of FY26, a significant drop from the ₹6.41 crore profit in the year-ago quarter. Revenue for Q3 FY26 was ₹12.3 crore, down from ₹51.62 crore in the previous two quarters.
Looking ahead, investors will monitor how Vaxfab Enterprises utilizes its newly raised capital and its contribution to future earnings. Future warrant conversion announcements and their impact on shareholding patterns will be important. The company's ability to manage operational efficiency and profitability amidst market fluctuations, alongside any further regulatory compliance updates, will also be key factors to track.